Sort
15,842 grants matching “pancreatic cancer”
Novel HDAC Class III Specific Radiotracers for PET Imaging.
$642,781Juri G Gelovani · Wayne State University · R01 · FY2014 · DA
Targeting anoctamin 6 to disrupt trogocytosis of cancer-associated fibroblasts
$642,755Igor Astsaturov · Research Inst Of Fox Chase Can Ctr · R01 · FY2025 · CA
Large scale clinical and economic impact analysis of potentially malignant incidental findings in radiology reports
$642,718Meliha Yetisgen · University Of Washington · R01 · FY2023 · CA
Foregut Microbiome and Risk of Gastric Intestinal Metaplasia, and Gastric Cancer Risk
$642,576Yu Chen · New York University School Of Medicine · R01 · FY2019 · CA
Protein and proteolytic activity biomarkers of early stage pancreatic cancer
$642,526Paul Tempst · Sloan-Kettering Inst Can Research · R01 · FY2017 · CA
PPARD hyperactivation promotes pancreatic intraepithelial neoplasia progression into pancreatic ductal adenocarcinoma
$642,368Imad Shureiqi · University Of Michigan At Ann Arbor · R01 · FY2025 · CA
Disclosing Genomic Incidental Findings in a Cancer Biobank: An ELSI Experiment
$642,347Gloria M. Petersen · Mayo Clinic Rochester · R01 · FY2012 · CA
Developing a pretargeting strategy to detect Fe(II) for nuclear medicine applications
$642,126Michael John Evans · University Of California, San Francisco · R01 · FY2023 · EB
North American Pancreatitis Study 2 (NAPS2)
$642,118University Of Pittsburgh At Pittsburgh · R01 · FY2002 · DK
Validation and Fine-Scale Mapping of Pancreatic Cancer Susceptibility Loci (Study)
$641,991Alison P Klein · Johns Hopkins University · R01 · FY2018 · CA
Total Neoadjuvant Therapy (TNT) for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
$641,782Alice Chia- Chi Wei · Sloan-Kettering Inst Can Research · P50 · FY2025 · CA
Project 2: Splicing Dysregulation in Cancer
$641,584Adrian R Krainer · Cold Spring Harbor Laboratory · P01 · FY2024 · CA
Therapeutic Targeting Mitochondrial C1 Metabolism
$641,436Larry H. Matherly · Wayne State University · R01 · FY2021 · CA
Phenotypic marker-guided development of selective antimetastasis therapeutic leads
$641,429Sui Huang · Northwestern University At Chicago · R01 · FY2025 · CA
Imaging Modulation of Immune Phenotype
$641,412Katherine W Ferrara · Stanford University · R01 · FY2023 · CA
Imaging Modulation of Immune Phenotype
$641,412Katherine W Ferrara · Stanford University · R01 · FY2022 · CA
Mechanisms of myeloid cell driven pancreatic plasticity and carcinogenesis
$640,945Marina Pasca Di Magliano · University Of Michigan At Ann Arbor · R01 · FY2025 · CA
Merging Marine-Derived Cytotoxic Natural Products With Experimental Therapeutics
$640,899Phil Crews · University Of California Santa Cruz · R01 · FY2016 · CA
The Antigen Targeting Core
$640,883Maria Parkhurst · Division Of Basic Sciences - Nci · ZIC · FY2019 · CA
Multiplexed dissection of metastatic ability, organ tropism, and immune evasion
$640,760Monte Meier Winslow · Stanford University · U01 · FY2025 · CA
Mitochondrial calcium signaling in pancreatic cancer metastasis and progression
$640,552Shengyu Yang · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2025 · CA
Molecular Determinants and Therapeutic Consequences of Immune Heterogeneity in Cancer
$640,513Robert H Vonderheide · University Of Pennsylvania · R01 · FY2019 · CA
Impact of Circadian-Microbiome Interaction on the Gut-Pancreas Axis in Aging
$640,435Faraz Bishehsari · University Of Texas Hlth Sci Ctr Houston · U01 · FY2025 · AG
Surrogate biomarkers for assessing changes in pancreatic cancer tumor microenvironment
$640,316Marvin M Doyley · University Of Rochester · R01 · FY2021 · EB
Real-time MRI-guided adaptive radiotherapy of unresectable pancreatic cancer
$640,178Ricardo Otazo · Sloan-Kettering Inst Can Research · R01 · FY2021 · CA